Today's Pharma Pulse
Updated 2h ago
AbbVie strikes up to $745M deal with China’s Haisco for pain pipeline
AbbVie has agreed to pay up to $745 million to Chinese biopharma Haisco for development, manufacturing and commercialization rights to early‑stage pain‑relief compounds outside China, Hong Kong and Macau. The agreement includes a $30 million upfront payment and up to $715 million in milestone fees, plus tiered royalties on future sales.
Also developing:
By the numbers: Quiver Bioscience lands strategic investment from Porta Family
Pfizer’s Oncology Sales Poised for Growth Ahead of Q1 Earnings
Pfizer is expected to report rising oncology sales in its Q1 2026 earnings, driven by strong performance of Xtandi, Lorbrena and the Braftovi‑Mektovi combo. The company’s recent Seagen acquisition and expanding biosimilar portfolio add further upside, while generic pressure on Ibrance could weigh on growth.
GSK Moves Ovarian Cancer ADC Mo-Rez Into Five Phase 3 Trials
GlaxoSmithKline said its experimental ovarian‑cancer antibody‑drug conjugate, Mo-rez, will be tested in five Phase 3 studies following encouraging early‑stage results. The move expands GSK’s oncology portfolio and signals a renewed focus on high‑unmet‑need cancers.
CRISPR Turns 25: Explore Its Past, Present, Future
Introducing the GEN Keynote Webinar: "CRISPR at 25: The Past, Present, and Future of Genome Editing" Guest speaker: Rodolphe Barrangou @CRISPRchef May 4, 2026: noon ET/9 am PT Sponsored by @elevatebio https://t.co/cYsSsaod4Y via @GENbio
FDA Zeroes in on Houman Hemmati for CBER Lead
FDA narrows in on search for new biologics and vaccines leader - and we’re hearing @houmanhemmati is a top contender for CBER - https://t.co/qMx8wv32fG
Big Pharma's Trust Gap? How Gilead Is Rewriting the Narrative | Next to Lead
The interview with Gilead Sciences’ Chief Commercial and Corporate Affairs Officer, Johanna Mercier, centers on the biotech giant’s effort to close a widening trust gap with the public while sustaining its rapid‑innovation model. Mercier highlights Gilead’s record‑setting FDA approval of...
Delaying Generics Boosts Profits Far More than Small Gaps
That gap doesn't look like it could be the largest price-fixing scam in history. it looks like 4% of a generic drug's price. Brand drugs sell for 10-20 times as much as generics, Delaying generic entry by even 6 months...
Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
The interview with Dr. Sarfaraz Niazi, CEO of RNA Therapeutics, explores his decades‑long journey from academia to industry and his pivotal role in shaping the biosimilar landscape. He recounts early work on biological drugs before the FDA had a formal...
2026 340B Program Update – 340B Rebate Model RFI Comments Due and Manufacturers Continue Restricting 340B Pricing
The Health Resources and Services Administration (HRSA) has extended the comment deadline for its proposed 340B rebate‑model pilot to April 20, 2026, giving covered entities extra time to outline operational and financial impacts. At the same time, Eli Lilly and Novo Nordisk have instituted...
Why Has Marijuana Not Been Rescheduled? The Answer Is Obvious, Kinda
President Trump issued an executive order to move cannabis from Schedule I to Schedule III, yet the Department of Justice has not finalized the rule after more than three months. A senior Trump adviser and GOP operative Roger Stone has publicly urged...
India Pushes Pharma Shift From Generic Volume to Biologics Innovation
Union Minister Anupriya Patel announced a $‑billion‑plus budget and regulatory reforms to steer India's pharmaceutical industry from a volume‑focused generics model toward biologics and biosimilars. The plan adds three new NIPER institutes and modernises the CDSCO, aiming to boost R&D...
EU Approves Dupixent for Children 2‑11 with Chronic Spontaneous Urticaria
Regeneron Pharmaceuticals and Sanofi announced that the European Commission has approved Dupixent for moderate‑to‑severe chronic spontaneous urticaria in children aged 2 to 11. The decision adds a new pediatric indication to the drug, which was already approved for adults and...
Vivatides Therapeutics Raises $54M for RNA Expansion
Vivatides Therapeutics announced a $54 million Series A round, led by Qiming Venture Partners and backed by several other investors. The funding will accelerate its proprietary extrahepatic delivery platform, designed to transport RNA molecules such as siRNA and antisense oligonucleotides beyond the...
Loyal Raises $100 Million: Dog Longevity Drugs Targeting IGF-1 and PPAR Pathways
Loyal, a veterinary biotech firm, announced a $100 million financing round to advance its canine longevity platform. The company targets the IGF‑1 and PPAR pathways to develop drugs that extend the lifespan of senior and large‑breed dogs. It has secured conditional...
Retail Pharmacies Fill Less than 2% of Mifepristone Orders
The FDA’s January 2023 removal of the in‑person dispensing rule let pharmacies, including mail‑order and retail outlets, fill mifepristone prescriptions. A USC study published in JAMA finds that only about 2,700 prescriptions are filled monthly, with mail‑order pharmacies handling more than...
F.D.A. Calls on Drug Developers to Publish Missing Data From Thousands of Trials
The FDA announced it has dispatched more than 2,200 letters to drug makers, device manufacturers and researchers, demanding the publication of clinical‑trial results that remain absent from ClinicalTrials.gov. An internal analysis shows roughly 30 % of studies under FDA review have...
FDA Narrows in on Search for New Biologics and Vaccines Leader
The U.S. Food and Drug Administration is close to naming a new director for its Center for Biologics Evaluation and Research (CBER), ending the turbulent tenure of Vinay Prasad. Sources say the leading candidate is Dr. Susan K. Lee, a...
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
The FDA issued a second complete response letter rejecting Replimune’s biologics license application for RP1 combined with nivolumab in advanced melanoma, citing insufficient data to isolate RP1’s contribution. Replimune’s CEO warned of job cuts and a scale‑back of U.S. manufacturing....
